University of California - Los Angeles Health Sciences Jul 8 2025 A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor–induced type 1 diabetes, a rare but life-threatening side effect of cancer immunotherapy, using an existing class of autoimmune drugs. The study, published in JCI Insight , identifies a new group of immune cells involved in the development immune checkpoint